UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-QSB

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES ACT OF 1934

For the quarterly period ended November 30, 2005

Commission File Number 0-12305

NEW YORK	13-3044880
(State or other jurisdiction of incorporation or organization)	(IRS Employer Identification No.)

24 CARPENTER ROAD, CHESTER, NY	10918
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code (845) 469-2042

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes (X) No ( )

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class	Outstanding at November 30, 2005
Common stock, $.01 par value	28,116,286 shares

REPRO-MED SYSTEMS, INC.

TABLE OF CONTENTS

PART I PAGE

ITEM 1. Financial Statements

Balance Sheet (Unaudited) - November 30, 2005 and February 28, 2005 (Audited) 3

Statements of Operations (Unaudited) - for the three-months and nine months ending November 30, 2005 and November 30, 2004 4

Statements of Cash Flow (Unaudited) - for the nine months ending November 30, 2005 and 2004 5

Notes to Unaudited Financial Statements 6

ITEM 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations 7

PART II

ITEM 1. Legal Proceedings 11

ITEM 2. Changes in Securities 11

ITEM 3. Defaults Upon Senior Securities 11

ITEM 4. Submission of Matters to a Vote of Security Holders 11

ITEM 5. Other Information 11

ITEM 6. Exhibits and Reports on Form 8-K 12

<TABLE>

REPRO-MED SYSTEMS, INC.
BALANCE SHEET

<CAPTION>

	NOVEMBER 30, 2005 (UNAUDITED)	FEBRUARY 28, 2005 (AUDITED)
<S>	<C>	<C>
ASSETS		
CURRENT ASSETS		
Cash & Cash Equivalents	$ 63,361	$ 37,330
Accounts Receivable, net	142,931	125,078
Inventory	337,463	371,569
Prepaid Expenses	25,290	36,531
TOTAL CURRENT ASSETS	569,045	570,508
PROPERTY & EQUIPMENT, NET	285,693	337,708
OTHER ASSETS		
Deposits	27,652	27,652
Other Assets	46,035	44,408
TOTAL OTHER ASSETS	73,687	72,060
TOTAL ASSETS	$ 928,425	$ 980,276
LIABILITIES & STOCKHOLDERS' EQUITY		
CURRENT LIABILITIES		
Accounts Payable	$ 276,518	$ 348,316
Notes Payable to Related Parties	7,000	7,000
Accrued Expenses	32,979	60,588
Note Payable to Bank	198,553	198,553
Accrued Payroll and Related Taxes	21,216	33,703
Accrued Interest	40,142	31,469
Accrued Preferred Stock Dividends	28,000	24,000
Current Portion Capital Lease Obligations	13,306	19,084
TOTAL CURRENT LIABILITIES	617,714	722,713
OTHER LIABILITIES		
Long-Term Portion of Leases Payable	--	10,381
Deferred Capital Gain Income	298,251	314,736
Long-Term Debt - Notes Payable	525,000	450,000

TOTAL LIABILITIES	1,440,965	1,497,830
STOCKHOLDERS' DEFICIENCY		
Preferred Stock, 8% Cumulative $.01 Par Value Authorized 2,000,000 Shares Issued & Outstanding 10,000 Shares (liquidation value $100,000)	100	100
Common Stock, $.01 Par Value, Authorized 50,000,000 Shares, 28,116,286 shares and 26,027,000 shares issued and outstanding at November 30, 2005 and February 28, 2005, Respectively	280,926	260,270
Additional Paid-in Capital	2,410,645	2,302,551
Accumulated Deficit	(3,062,211)	(2,938,475)
Treasury Stock at Cost	(142,000)	(142,000)
TOTAL STOCKHOLDERS' DEFICIENCY	(512,540)	(517,554)
TOTAL LIABILITIES & STOCKHOLDER'DEFICIENCY	$ 928,425	$ 980,276

See Accompanying Notes to Financial Statements

</TABLE>
<TABLE>

REPRO-MED SYSTEMS, INC.
STATEMENTS OF OPERATIONS
UNAUDITED

<CAPTION>

	FOR THE 3 MONTHS ENDED		FOR THE 9 MONTHS ENDED	
	NOV 30, 2005	NOV 30, 2004	NOV 30, 2005	NOV 30, 2004
<S>	<C>	<C>	<C>	<C>
SALES				
Net Sales of Products	$ 528,194	$ 337,141	$ 1,329,832	$ 1,211,091
COST AND EXPENSES				
Cost of Goods Sold	183,171	160,409	541,913	554,068
Selling, General & Administrative Expenses	223,672	258,763	718,698	727,999
Research and Development	10,118	10,943	31,470	32,615
Stock-Based Compensation	1,250	--	43,750	20,000
Depreciation and Amortization	19,252	20,079	59,687	61,334
TOTAL COST AND EXPENSES	437,463	450,194	1,395,518	1,396,016
INCOME (LOSS) FROM OPERATIONS	90,731	(113,053)	(65,686)	(184,925)
Non-Operating Income (Expense)				
Interest (Expense)	(20,309)	(15,047)	(57,626)	(41,057)
Interest & Other Income	--	6,517	3,578	14,179
	(20,309)	(8,530)	(54,048)	(26,878)
INCOME (LOSS) BEFORE INCOME TAXES	70,422	(121,583)	(119,734)	(211,803)
Provision for Income Taxes	0	0	0	(1,000)

NET INCOME (LOSS) AFTER TAXES ...	$ 70,422	$ (121,583)	$ (119,734)	$ (212,803)
NET (LOSS) PER COMMON SHARE				
Primary	$ 0.01	$ (0.01)	$ (0.01)	$ (0.01)
Fully Diluted	$ 0.01	$ (0.01)	$ (0.01)	$ (0.01)
Average Common Shares Outstanding	27,353,191	24,931,000	26,744,064	24,876,600

See Accompanying Notes to Financial Statements

</TABLE>
<TABLE>

REPRO-MED SYSTEMS, INC.
STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED
UNAUDITED

<CAPTION>

	NOVEMBER 30, 2005	NOVEMBER 30, 2004
<S>	<C>	<C>
CASH FLOWS FROM OPERATING ACTIVITIES		
Net (Loss)	$(119,734)	$(212,803)
Adjustments to reconcile net (loss) to cash (used) in operating activities:		
Stock-Based Compensation	43,750	20,000
Legal Expenses Charged to Additional Paid-In Capital	-	(10,000)
Depreciation and Amortization	59,687	61,333
Capital Gain - Building Lease	(16,485)	(16,859)
Increase in Accounts Receivable	(17,853)	16,835
Decrease in Inventory	34,106	(3,752)
Increase (Decrease) in Prepaid Expenses	11,241	(17,937)
Decrease in Accounts Payable	(71,798)	(33,189)
Decrease in Accrued Expenses	(31,323)	(7,242)
NET CASH USED IN OPERATIONS	(108,409)	(203,614)
CASH FLOWS FROM INVESTING ACTIVITIES		
Decrease in Security Deposit	--	--
Capital Expenditures	(9,401)	(31,173)
NET CASH USED IN INVESTING ACTIVITIES	(9,401)	(31,173)
CASH FLOW PROVIDED BY FINANCING ACTIVITIES		
Issuance of Common Stock at $0.07per share	85,000	--
Notes Payable - President and Others	75,000	100,000
Payments, Increased Obligations on Capitalized Leases	(16,159)	(15,238)
NET CASH PROVIDED BY FINANCING ACTIVITIES	143,841	84,762
NET INCREASE IN CASH	26,031	(150,025)
Cash and Cash Equivalents, beginning of period	37,330	219,682
Cash and Cash Equivalents, end of period	$ 63,361	$ 69,657
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:		
Interest	$ 48,953	$ 41,057
Income Taxes	--	1,000

Non-Cash Investing and Financing Activities:		
Preferred Stock Dividend Payable	$ 4,000	$ 4,000

See Accompanying Notes to Financial Statements

</TABLE>

REPRO-MED SYSTEMS, INC.
NOTES TO THE FINANCIAL STATEMENTS
UNAUDITED

BASIS OF PRESENTATION

The accompanying unaudited condensed financial statements have been prepared in accordance with generally accepted accounting principles for interim financial statements and with instructions to Form 10-QSB. Accordingly, they do not include all of the information and disclosures required for annual financial statements. These financial statements should be read in conjunction with the financial statements and related footnotes for the year ended February 28, 2005 included in the Form 10-KSB for the year then ended.

In the opinion of the Company's management, all adjustments (consisting of normal recurring accruals) necessary to present fairly the Company's financial position as of November 30, 2005, and the results of operations and cash flows for the three month and nine month periods ended November 30, 2005 and 2004 have been included.

The results of operations for the nine-month period ended November 30, 2005, are not necessarily indicative of the results to be expected for the full year. For further information, refer to the financial statements and footnotes thereto included in the Company's Form 10-KSB as filed with the Securities and Exchange Commission for the year ended February 28, 2005.

In March, 2003, the Company negotiated with the landlord of its Chester, New York, facility to utilize $27,500 of its security deposit (held by the landlord) to pay March and April, 2003, rent. The agreement provides for replenishment within 90 days. At the date of this filing, the security deposit had not been repaid.

STOCKHOLDERS' EQUITY/NOTES PAYABLE

During the quarter ended May 31, 2005, the company executed note agreements for $80,000. In connection with the execution of those agreements, the Company is obligated to issue four shares of its common stock each year for each dollar of principal borrowed. The Company is obligated to issue 425,000 shares of its common stock under the agreements. As of November 30, 2005, 185,000 of these shares have been issued and the remaining 245,000 shares have been reflected as issued for financial statement purposes.

GOING CONCERNS

As shown in the accompanying final statements, the Company has incurred cumulative losses of $3,062,211 and has negative working capital of $(48,669) at November 31, 2005. The Company is seeking to raise additional working capital through debt or equity channels and is working with outside distributors to increase its market share in the European and U.S. markets. However, even if the Company does raise capital through the debt or equity channels or increase its sales through new strategies, there can be no assurances that the net proceeds of the capital raised or the revenue generated from new marketing strategies will be sufficient to enable it to develop business to a level when it will generate profits and cash flow from operations.

These matters raise substantial doubt about the Company's ability to continue as a going concern. However, the accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

PART I ITEM 2.

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Quarterly Report on Form 10-QSB contains certain "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) and information relating to us that are based on the beliefs of the management, as well as assumptions made by and information currently available. Our actual results may vary materially from the forward-looking statements made in this report due to important factors such as, recent operating losses, uncertainties associated with future operating results, unpredictability related to Food and Drug Administration regulations, introduction of competitive products, limited liquidity, reimbursement related risks, government regulation of the home health care industry, success of the research and development effort, market acceptance of FREEDOM60, availability of sufficient capital to continue operations and dependence on key personnel. When used in this report, the words "estimate," "project," "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. Such statements reflect current views with respect to future events based on currently available information and are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. These statements involve risks and uncertainties with respect to the ability to raise capital to develop and market new products, acceptance in the market place of new and existing products, ability to penetrate new markets, our success in enforcing and obtaining patents, obtaining required Government approvals and attracting and maintaining key personnel that could cause the actual results to differ materially. Repro-Med does not undertake any obligation to release publicly any revision to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

THREE MONTHS ENDED NOVEMBER 30 2005 VS. 2004
- ----------

Total sales increased by 56.7% ($191,053) from $337,141 to $528,194 for the three month period ending November 30,2005.

Net Income from operations shows a profit of $90,731 for the three months ending November 30,2005 as compared to a loss of $113,053 for the same quarter in 2004 and represents a total improvement of $203,784 between the two quarters. Net income after taxes showed a profit of $70,422 as compared to a loss of $121,583 for the three months ended November 30, 2004.

RES-Q-VAC and Freedom60 represent the company's key products. Domestic sales of the RES-Q-VAC product line increased 254% quarter over quarter ended November 30, 2005, primarily due to a large government order placed in response to the hurricane Katrina aftermath which occurred during the period, and due to unusually low sales during the prior year's quarter. Overall, RES-Q-VAC had a net increase of 60% as our international sales had declined 27% quarter over quarter which we attribute to the economies in Europe and competition entering the markets there.

Freedom60 experienced a net increase of 35% quarter over quarter ended November 30, 2005 due to several major new accounts added during the year. OEM sales increased this quarter by 295% due to new sales for a custom product in the veterinary market. Sales of our Gyneco products remained essentially flat quarter over quarter increasing by 2%.

Gross profit margin increased to 65.3% compared to 52.4% of net sales three months year over year ending November 30, 2005, due to improved efficiencies in production, reclassification of certain cost of goods, and lower labor levels during the period.

Selling, general and administrative expense decreased 13.6% from $258,763 to $223,672 over this period due primarily to reduced labor. Research and development expenses remained nearly level, decreasing slightly by $825 from $10,943 in 2004 to $10,118 for the three month period ending November 30, 2005.

Interest expense increased 35% ($5,262) due to an increase in loans obtained through the company's promissory note program.

NINE MONTHS ENDED NOVEMBER 30, 2005 VS. 2004
- ----------

Net sales increased 9.8% overall to $1,329,832 in 2005 from $1,211,091 in 2004 for the ninth month period ending November 30th, 2005. For the nine months ended November 30, 2005 the increase in the domestic sales of RES-Q-VAC of 31% were offset by the decrease of the international sales of 20%, resulting in an overall Res-Q-Vac sales increase of 0.5%. Sales of the products in the Freedom60 line increased by 27% during the same period. Sales of the OEM products increased 198% due to new sales of an OEM device for the veterinary market. Sales in the Gyneco product line continue to decrease and declined by 10% for the nine months ending November 30, 2005 as compared to the same period in 2004.

Gross profit increased to 59.2% of net sales in 2005 from 54.3% in 2004 due to greater efficiencies in production and lower labor.

Selling, general and administrative expense decreased slightly from $727,999 to $718,698 over the same period. Research and development expenses remained nearly level, decreasing slightly by $1,145 from $32,615 in 2004 to $31,470 for the nine month period ending November 30, 2005.

Depreciation and amortization expense decreased by $1,647 period over period as the result of fewer equipment purchases during the past year.

Interest expense increased 40.4% ($16,569) as a result of an increase in loans obtained through the company's promissory note program.

Other income decreased $10,601, period over period.

The net loss for the nine months ended November 30, 2005 decreased 43.7% to $119,734 from $212,803.

LIQUIDITY AND CAPITAL RESOURCES
- ----------

During June 2000, we negotiated a $200,000 line of credit with M&T Bank that is guaranteed by the President and one of the directors. As of November 30, 2005, $198,553 has been advanced on the line of credit. Although the line expired on June 30, 2002, the bank verbally extended the line through June 30, 2003. We are requesting the bank to extend the line for another six months. We have not received a demand for repayment of the loan and continue to make interest payments.

Commencing in mid-February, 2004, we started raising capital from a promissory note and stock offering which raised $225,000 by the end of the fiscal year ended February 29, 2004. This five-year promissory note pays 2% over prime plus four shares of common stock per year for every year the loan is in place. We received an additional $100,000 under the same program in the first quarter of fiscal year 2005. Another $25,000 was raised in the first quarter of 2003 under similar terms.

In September and October, 2005, we sold common stock to two independent investors totaling $85,000.

We continue to work towards improving cash flow and have several opportunities to improve sales of our key products, RES-Q-VAC and FREEDOM60. We have expanded our sales efforts in several areas.

RES-Q-VAC
- ---------

We have added several features to the RES-Q-VAC which make the product much more interesting not only in the current markets but in several new markets as well. The first of these improvements is the addition of FULL STOP PROTECTION (FSP) to the RES-Q-VAC, which protects the users from any contamination from overflow and traps all pathogens inside the suction container. This feature is also a requirement of the Occupational Safety and Health Administration under OSHA 29CFR 1910.1030 - Occupational Exposure to Bloodborne Pathogens. The RES-Q-VAC

is the only hand-held non-electric suction system with sterile catheters for infants, large catheters for adults, and meets the intent of the OSHA requirements with the FSP device. The Company has received a letter from OSHA confirming that the Full Stop Protector falls under the engineering controls of the Bloodborne Pathogen regulation and therefore would be required by any employer of medical personnel to protect their employees from potentially infectious materials. The Centers for Disease Control in Atlanta have issued guidelines for medical personnel for the treatment of patients with SARS which include the recommendation to employ suction devices containing HEPA type filtration on the output to prevent the spread of this disease. We believe RES-Q-VAC is the only hand-held portable suction system which meets this requirement.

We have also added new sturdier connectors to our pediatric catheters, which allow them to connect directly to the adult containers with FSP. These connectors allow pediatric suctioning with the benefit of the full protection FSP device as well as with sterile catheters. These improved features come at a lower cost for the user, and a more compact kit for easier transport. Many infants are born with contagious diseases and the new system eliminates this concern among paramedics during an emergency delivery. The adult large bore yankuer is also fitted with an improved connector, for easier changeability and convenience.

We have begun upgrading our RES-Q-VAC distribution channels by selecting key distributors to work with as master distribution outlets. The domestic emergency medical market has softened due to a decrease in Federal reimbursement to state and city regional areas. We have concluded that we can have more effective market penetration with major master distributors who will have much greater sales volume and be able to better support our products. In the domestic market, there are currently two major distributors who have expressed interest in working with us in this capacity, and we are moving aggressively towards finalizing these arrangements.

We are also moving to consolidate international RES-Q-VAC distribution, as well, by selecting one or two master distributors in each country. We already have master distribution in Norway, Sweden, Denmark, Iceland, Finland, Estonia, Latvia, and Lithuania. We have added single-point distribution in the United Kingdom for RES-Q-VAC with ABC Healthcare, LTD who will also begin marketing the Freedom60 in Europe. We believe that one main distributor will be more predisposed to advertising, promotion, and building the product franchise in each market. In return, we will be able work more closely with the distributors and be able to hold them accountable for the sales in each region.

We have begun a major sales effort into the nursing home market for the RES-Q-VAC. The features of Full Stop Protection to meet OSHA requirements, sterile catheters, and the ability of RES-Q-VAC to work during extended power outages, have created a receptive market, especially in regions which recently have had major power outages, such as Florida with the recent hurricanes and the blackout in the Northeast. Patients on ventilators, tracheotomy patients, elderly with swallowing disorders, stroke, heart attack, choke victims--all may need prompt effective suctioning wherever they are and for whom RES-Q-VAC may be life saving. This includes locations such as dining rooms, recreations areas, transportation and outdoor activities, among others.

In the third quarter we began advertising as well as an extensive mail and telephone marketing program to introduce RES-Q-VAC to the nursing home market. After a one-time mailing to seven states, we have received more than 100 direct responses, with several being national and regional accounts involving potentially hundreds of additional nursing homes, and resulting in a number of new customers during the past several weeks. We plan to continue the mail and telemarketing to the greatest extent possible with our resources.

Additional new markets we have recently sold into include schools, and hospital-based respiratory centers. We plan mailings into those markets, as well. In the school market, we have been informed that any school with a swimming pool is normally required to have suction equipment available. In addition, many schools are installing automatic electronic defibrillators (AED's) for which suction is needed in more than 50% of uses for this device. Our mailings to nursing homes also resulted in some interest by respiratory centers, and we believe there may be additional sales opportunities in this market.

FREEDOM60
- ---------

We recently signed an agreement with Innovatix, a full-service group purchasing organization with 6,000 alternate care members who are primarily infusion providers and we have begun a program to reach all their members. The decrease in reimbursement continues to encourage home health care providers to seek out effective lower cost infusion systems. There is significant interest for the Freedom60 for use with Immune Globulin, a treatment for Primary Immune deficiency. This is a potentially large new market for which our system is ideally suited. Recently, ZLB Behring announced FDA approval of VIVAGLOBIN(r). This is the first subcutaneous immunoglobulin replacement therapy approved in the U.S. With the drug approval, increasing use of the Freedom60 is expected with national and regional providers to this market.

TRADE SHOWS
- -----------

We continue to support our products at several trade shows. In November, we exhibited with our UK Distributor for the Freedom60 at an infusion trade show in Brighton and then we attended the Medica Trade Show in Dusseldorf, Germany, the world's largest medical products trade show. In March, 2006, we are scheduled to exhibit our Freedom60 at the annual National Home Infusion Association conference as well as Vital Care. If resources permit, we plan to attend the EMS Today Show for the RES-Q-VAC, also in March.

OTHER
- -----

We continue to pursue capital investment through debt or equity to increase our marketing and sales efforts, and to enhance our existing products and add to product lines.

Our Freedom60 Syringe Infusion System is in the process of being evaluated by the Bath Institute of Medical Engineering (BIME) in the United Kingdom for eventual sale in that market. We have also added new RES-Q-VAC distributors in several countries including Croatia, Dubai, Turkey, Hong Kong and China as a result, in part, of our presence at the Medica trade show in Dusseldorf, Germany, and our ongoing international sales efforts.

PART II - OTHER INFORMATION
- --------------------------

ITEM 1. LEGAL PROCEEDINGS

The Company is neither a party to any material litigation, nor to the knowledge of the officers and directors of the Company, is there any material litigation threatened against the Company.

However, It has been brought to management's attention that one of the company's German distributors had commenced selling a copy, manufactured in China, of our basic RES-Q-VAC. The distributor has agreed to cease selling these copies but we are concerned about the possibility of these copies appearing elsewhere.

Although we believe that the Chinese copy is inferior in quality and lacks Full Stop Protection, it is being offered at a lower price and could adversely affect our sales in international markets.

ITEM 2. CHANGES IN SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

No matters were submitted to a vote of security holders of the Company during

the quarter ended November 30, 2005.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) Exhibits

31.1 Certification of Chief Executive Officer and Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1 Certification of Chief Executive Officer and Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

(b) Reports on Form 8-K

SIGNATURES

Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934 the Registrant has duly caused this report to be signed on its behalf by the undersigned; thereunto duly authorized.

REPRO-MED SYSTEMS, INC.

/s/ Andrew I. Sealfon January 23, 2006
- ----------
Andrew I. Sealfon, President, Treasurer,
Chairman of the Board, Director, and
Chief Executive Officer

EXHIBIT 31.1
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Andrew I. Sealfon, certify that:

1. I have reviewed the Form 10-QSB of Repro-Med Systems, Inc. (the "Report");

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the small business issuer as of, and for, the periods presented in this report;

4. The small business issuer's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the small business issuer and have:

(a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) evaluated the effectiveness of the small business issuer's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(c) disclosed in this report any change in the small business issuer's internal control over financial reporting that occurred during the small business issuer's most recent fiscal quarter (the small business issuer's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the small business issuer's internal control over financial reporting; and

5. The small business issuer's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the small business issuer's auditors and the audit committee of the small business issuer's board of directors (or persons performing the equivalent functions):

(a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer's ability to record, process, summarize and report financial information; and

(b) any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer's internal control over financial reporting.

Date: January 23, 2006

/s/ Andrew I. Sealfon
Andrew I. Sealfon
Chief Executive Officer and Principal Financial Officer

EXHIBIT 32.1
CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Repro-Med Systems, Inc. (the "Company") on Form 10-QSB for the period ending November 30, 2005, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Andrew I. Sealfon, Chief Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) the information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Andrew I. Sealfon
Andrew I. Sealfon
Chief Executive Officer and
Principal Financial Officer

January 23, 2006